<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT933-9407</title>
	</head>
	<body>
		<main>
			<p>930810 FT  10 AUG 93 / International Company News: Chugai Pharmaceutical Chugai Pharmaceutical, a leading Japanese drugs company, has attributed a rise in mid-term profits to brisk sales of its new renal anaemia drug, writes Emiko Terazono in Tokyo. Chugai's non-consolidated pre-tax profits for the six months to June rose 10.2 per cent, to Y6.3bn (Dollars 60.29m), on a 6.4 per cent rise in sales to Y73.1bn. After-tax profits jumped 40.5 per cent to Y2.9bn, although the previous year the company recorded the losses on affiliates' investments. Sales of Chugai's renal anaemia drug, which rose by more than 30 per cent for the first half, offset costs from the company's equity-linked financing, it said.</p>
		</main>
</body></html>
            